CX3CL1 Blocking Peptide for STJ500636 is synthetically produced from the 350-395 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid reigon 350-395 on mouse Fractalkine protein.
Immunogen Region
350-395
Specificity
This blocking peptide is recommended for use in combination with CX3CL1 antibody, STJ500636
Additional Info
Tissue Specificity
Highest levels in brain. Lower levels in kidney, heart and lung. Also found in skeletal muscle and testis. Highly expressed in lesional smooth muscle cells, but not macrophages. Low levels of ABCD-3 mRNA were also found in anti-CD40-stimulated splenic B-cells, but not in resting B-cells. Also expressed in dendritic cells.
Post Translational Modifications
A soluble short 80 kDa form may be released by proteolytic cleavage from the long membrane-anchored form.
Function
Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. The CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis. Regulates leukocyte adhesion and migration processes at the endothelium. Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1. Processed fractalkine: The soluble form is chemotactic for T-cells and monocytes, but not for neutrophils. Fractalkine: The membrane-bound form promotes adhesion of those leukocytes to endothelial cells.
